Abstract
A number of recent publications have shown that secondary prevention of cerebrovascular ischemic brain events is possible with anti-aggregating drugs. Comparison between the different studies is difficult, but the results obtained with using a combination therapy with aspirin (ASA) and dipyridamole (DP) seem to be superior to the results obtained with ASA alone. The first European Stroke Prevention Study (ESPS 1), that used 990 mg ASA and 225 mg DP a day, showed this clearly. In an attempt to minimize the side effects of a large dose ASA and possibly even to improve the efficacy, ESPS 2 was established. ESPS 2 will compare 50 mg ASA, 400 mg DP, the combination of both, and placebo. Biomedical Reviews 1993; 2: 31-35.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
